GENEVA, Switzerland, Oct. 11, 2012 /CNW/ - Merck Serono, a division of
Merck, Darmstadt, Germany, announced today during the European
Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
congress in Lyon, France, that the company has initiated a new global
research award to improve understanding of multiple sclerosis for the
ultimate benefit of patients.
The Grant for Multiple Sclerosis Innovation program will award up to one
million euros annually to fund innovative research into multiple
sclerosis (MS) by academic researchers. Researchers can submit their
project proposals via the program's website, www.grantformultiplesclerosisinnovation.org, and awardees will be announced at next year's ECTRIMS congress in
"We are committed to driving innovative research to further contribute
to our understanding of the disease and ultimately lead to new medical
breakthroughs in multiple sclerosis," said Annalisa Jenkins, Head of
Global Drug Development and Medical for Merck Serono. "While tremendous
progress has been made over the years, we must continue to search for
answers to important scientific questions in the field."
Potential research topics which could be funded through the Grant for
Multiple Sclerosis Innovation include MS pathogenesis, predictive
markers for treatment response and potential new treatments.
This grant complements other existing programs like Merck Serono's
collaboration with the National Multiple Sclerosis Society, the
FastForward™* collaborative fund.
The funds from the Grant for Multiple Sclerosis Innovation will be
awarded by EMD Serono for projects based in the United States and
Canada and by Merck Serono to those based in the rest of the world.
For more information about the program, and to submit a scientific
research project proposal, please visit, www.grantformultiplesclerosisinnovation.org.
*For more details related to FastForward™, please visit: http://www.nationalmssociety.org/fast-forward
About EMD Serono, Canada
EMD Serono is a Division of EMD Inc., Canada. EMD Inc., Canada, is an
affiliate of Merck KGaA, Darmstadt, Germany. In Canada, EMD Serono
provides innovative drug therapies that address unmet medical needs in
the areas of neurodegenerative diseases, fertility and endocrinology.
EMD Serono employs approximately 150 people across Canada and is
headquartered in Mississauga, Ontario. For more information, please
About Merck Serono
Merck Serono is the biopharmaceutical division of Merck KGaA. With
headquarters in Darmstadt, Germany, Merck Serono offers leading brands
in 150 countries to help patients with cancer, multiple sclerosis,
infertility, endocrine and metabolic disorders as well as
cardiovascular diseases. In the United States and Canada, EMD Serono
operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription
medicines of both chemical and biological origin in specialist
indications. We have an enduring commitment to deliver novel therapies
in our core focus areas of neurodegenerative diseases, oncology and
Merck is a global pharmaceutical and chemical company with total
revenues of €10.3 billion in 2011, a history that began in 1668, and a
future shaped by more than 40,000 employees in 67 countries. Its
success is characterized by innovations from entrepreneurial employees.
Merck's operating activities come under the umbrella of Merck KGaA, in
which the Merck family holds an approximately 70% interest and free
shareholders own the remaining approximately 30%. In 1917 the U.S.
subsidiary Merck & Co. was expropriated and has been an independent
company ever since.
For more information, please visit www.merckserono.com or www.merckgroup.com
SOURCE: EMD Serono
For further information:
Tel. 1 905-919-0200 ext 5504